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ABSTRACT
Correction of human myeloid cell function is crucial for the prevention of inflammatory 
and allergic reactions as well as leukaemia progression. Caffeine, a naturally occurring 
food component, is known to display anti-inflammatory effects which have previously 
been ascribed largely to its inhibitory actions on phosphodiesterase. However, more 
recent studies suggest an additional role in affecting the activity of the mammalian target 
of rapamycin (mTOR), a master regulator of myeloid cell translational pathways, although 
detailed molecular events underlying its mode of action have not been elucidated. 
Here, we report the cellular uptake of caffeine, without metabolisation, by healthy and 
malignant hematopoietic myeloid cells including monocytes, basophils and primary 
acute myeloid leukaemia mononuclear blasts. Unmodified caffeine downregulated mTOR 
signalling, which affected glycolysis and the release of pro-inflammatory/pro-angiogenic 
cytokines as well as other inflammatory mediators. In monocytes, the effects of caffeine 
were potentiated by its ability to inhibit xanthine oxidase, an enzyme which plays a 
central role in human purine catabolism by generating uric acid. In basophils, caffeine 
also increased intracellular cyclic adenosine monophosphate (cAMP) levels which further 
enhanced its inhibitory action on mTOR. These results demonstrate an important mode 
of pharmacological action of caffeine with potentially wide-ranging therapeutic impact 
for treating non-infectious disorders of the human immune system, where it could be 
applied directly to inflammatory cells.
INTRODUCTION
Caffeine (1,3,7-trimethylxanthine) is a purine alka-
loid present in the leaves, seeds or nuts of a number of 
plants and is consumed by many people worldwide on a 
daily basis due to its presence in tea or coffee. In humans, 
caffeine is rapidly demethylated by cytochrome P450 
isoform 1A2 and then converted mostly into methylated 
derivatives of uric acid by the enzyme xanthine oxidase 
(XOD) [1]. For a long time caffeine was recognised as 
an isosteric inhibitor of cyclic adenosine monophosphate 
phosphodiesterase (cAMP-PDE) which upregulates intra-
cellular cAMP levels [2]. Caffeine was also found to 
reduce the role of glycolysis in cell energy metabolism 
via upregulation of lipid degradation (lipolysis) [3, 4].
Recent evidence demonstrated that human 
hematopoietic cells do not express the cytochrome P450 
1A2 isoform and thus should not be able to metabolise 
caffeine, resulting in the effects of unmodified caffeine 
[5]. In this case, caffeine could competitively inhibit 
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XOD [6] rather than act as its substrate (most of the other 
methylxanthines can be converted by XOD). Moreover, 
several stable purines including caffeine were recently 
found to inhibit the activity of the mammalian target of 
rapamycin (mTOR) in somatic cells [7, 8]. It was also 
demonstrated that at high concentrations (5 mM), caffeine 
is capable of inhibiting the mTOR pathway in HOS 
osteosarcoma cells [7]. In addition, 10 mM caffeine was 
able to inhibit the PI3K/Akt/mTOR/p70S6K pathway in 
various cell lines including SH-SY5Y neuroblastoma cells 
and HeLa cells [9]. 10 mM caffeine was even capable of 
inhibiting the phosphorylation (Ser473) of Akt in SH-SY5Y 
cells [9]. In myeloid cells mTOR, a highly conserved serine/
threonine kinase, acts as a central regulator of cell growth 
and metabolism and plays crucial pathophysiological roles 
in host immune defence, allergic reactions and leukaemia 
[10]. Importantly, the mTOR pathway plays a pivotal role 
in non-hypoxic activation of the hypoxia-inducible factor 
1 (HIF-1) transcription complex in human myeloid cells. 
HIF-1 controls the expression of over 40 target genes 
responsible for glycolysis, angiogenesis and cell adhe-
sion – physiological processes which form a critical part 
of myeloid cell function in the human immune system. 
This transcription complex, containing an inducible α and a 
constitutive β subunit, is a major component of the myeloid 
cell stress adaptation machinery [11, 12]. Therefore, 
inhibiting the mTOR/HIF-1 metabolic/signalling axis could 
be an excellent therapeutic strategy for treating human 
disorders associated with myeloid cell function – leukaemia, 
autoimmune disease, and allergy. However, existing mTOR 
inhibitors are toxic and can cause major side effects and 
adverse drug reactions. Thus, if the inhibitory activity of 
caffeine on mTOR has indeed been overlooked for decades, 
this agent may be an excellent non-toxic drug candidate for 
the correction of pathophysiological responses of human 
hematopoietic cells of myeloid lineage.
Here we report for the first time that caffeine 
inhibits the activation of mTOR in THP-1 human myeloid 
leukaemia cells, primary human acute myeloid leukaemia 
(AML) cells and primary human basophils. In THP-1 
and primary AML cells caffeine was also found to inhibit 
XOD. In all cases, the caffeine-mediated attenuation of 
the mTOR pathway led to the downregulation of ligand-
induced glycolysis and cytokine/growth factor/mediator 
production. Caffeine is known to upregulate lipolysis 
through activation of hormone sensitive lipase (HSL). 
This upregulates the Krebs’ cycle leading to decreased 
intracellular levels of 2-oxoglutarate (2-OG), thus 
preventing degradation of HIF-1α protein (the inducible 
HIF-1 subunit) by a classical mechanism controlled by 
HIF-1α prolyl hydroxylases (PHDs). This effect was 
observed in all of the myeloid cell types studied except 
for basophils, where HIF-1α accumulation was less 
PHD-dependent and caffeine completely blocked IgE-
induced HIF-1α accumulation. High performance liquid 
chromatography (HPLC) experiments demonstrated that 
caffeine entered all of the above cell types and was not 
metabolised. Taken together, our results reveal novel 
mechanisms for the downregulatory effects of caffeine on 
the biological responses of human myeloid cells.
RESULTS
Caffeine inhibits ligand-induced activation of the 
mTOR pathway and its downstream effects in 
THP-1 human AML cells
We first investigated the effects of caffeine on ligand-
induced mTOR activation through phosphorylation of its 
S2448 residue in THP-1 cells. Cells were exposed for 4 h 
to ligands (see below) with or without 1 h pre-treatment 
with 1 mM caffeine (this concentration corresponds 
to a therapeutic dose of caffeine and is well below the 
toxic dose [13]). In line with our previous observations 
[10], we found that pro-inflammatory ligands of Toll-
like receptors (TLRs) 2 (plasma membrane-associated 
TLR – 1 μg/ml peptidoglycan (PGN) was used as a ligand), 
7/8 (endosomal TLRs recognising viral single-stranded 
RNA – 0.1 μg/ml resiquimod (R848) was employed as a 
ligand) induce activating S2448 phosphorylation of mTOR. 
The same effect was observed for stem cell factor (SCF), 
a major hematopoietic factor which is also known to 
promote growth of leukaemia cells, where caffeine (1 mM) 
attenuated its effect in all cases (Figure 1). Intriguingly, 
caffeine alone did not significantly reduce phospho-S2448 
mTOR in non-stimulated cells but significantly reduced 
background levels of phospho-T389 p70 S6K1 and 
phospho-S65 eIF4E-BP1 (see Figure 1 for details). This 
suggests that caffeine is likely to act directly on mTOR 
as well, which would prevent further phosphorylation but 
not impact on existing activity. The presence of caffeine 
close to the catalytic site (in the active site of mTOR) 
would almost certainly affect its kinase activity. However, 
it is important to stress that phosphorylation of mTOR at 
the inhibitory T2446 site was not increased by caffeine. 
This observation clearly suggests that caffeine is unlikely 
to enhance the activity of this mTOR downregulatory 
pathway and is likely to be a potential direct mTOR 
inhibitor, as some other purine containing compounds (such 
as cAMP) do [8]. Phosphorylation levels of its substrates 
(indicators of mTOR kinase activity) – p70 S6 kinase 1 (p70 
S6K1 – at position T389) and eukaryotic initiation factor 
4E-binding protein 1 (eIF4E-BP1 at position S65) were 
also significantly upregulated by all the employed ligands 
as well as phosphorylation of S2448 mTOR. All these 
processes were attenuated by caffeine (Figure 1).
We next investigated the effects of caffeine on 
mTOR downstream and associated biochemical pathways 
induced by PGN, R848 and SCF. We found that caffeine 
did not downregulate PGN-induced accumulation of 
HIF-1α protein. This was in line with a significant 
decrease in HIF-1α PHD activity in cells treated with PGN 
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Figure 1: Caffeine inhibits the ligand-induced mTOR signalling pathway in THP-1 human acute myeloid leukaemia 
cells. Cells were exposed for 4 h to the indicated concentrations of PGN, R848 or SCF with or without 1 h pre-treatment with 1 mM 
caffeine. Levels of pS2448 and pT2446 phospho-mTOR as well as phosphorylation of its downstream enzymes were analysed as outlined 
in the Materials and Methods. Western blot data show one representative experiment of four that gave similar results and were quantitatively 
analysed. Quantitative data are shown as means ± S.D; * – p < 0.01 vs. control (n = 4), a – p < 0.01 vs. PGN alone, b – p < 0.01 vs. R848 
alone and c – p < 0.01 vs. SCF alone.
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in the presence of caffeine (Figure 2A). ATP levels, which 
are often controlled in a HIF-1-dependent manner, were 
decreased in cells co-stimulated with PGN and caffeine. 
Levels of cAMP did not undergo significant changes, 
probably owing to the fact that receptors involved in 
these events are not G-protein-coupled [14]. They do not 
provoke adenylate cyclase activation/cAMP production 
and thus cAMP-PDE-inhibiting activity of caffeine has 
no effect in this case. AMP levels were also not increased 
by PGN stimulation, which conforms with our previous 
observations (Figure 2B). The presence of caffeine did 
not increase AMP levels despite a significant decrease in 
PGN-induced XOD activity (Figure 2C). This is likely 
to be caused by the inhibition of hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT), an enzyme which 
converts hypoxanthine (accumulated when XOD was 
inhibited) into inosine monophosphate (IMP), which 
is then converted into AMP [15, 16]. However, we 
could not rule out the possibility of caffeine-dependent 
effects on other enzymes involved in the conversion of 
hypoxanthine into AMP. Intracellular reactive oxygen 
species (ROS) levels upregulated by PGN were also 
unaffected by caffeine, possibly because XOD is not the 
main contributor to the intracellular ROS pool (NADPH 
oxidase plays this role [17]) in this case (Figure 2C). 
Glycolysis, which was significantly upregulated by 
PGN, was reduced to its basic level (Figure 2D). This is 
not surprising, since translation of glycolytic enzymes 
is likely to be an mTOR-dependent process in human 
hematopoietic cells [18]. However, intracellular 2-OG 
levels were almost completely abolished by caffeine 
(Figure 2D). This may be due to the caffeine-dependent 
upregulation of lipolysis and, therefore, the Krebs’ cycle 
(which would lead to a reduction of intracellular 2-OG 
levels and a subsequent decrease in 2-OG-dependent 
HIF-1α PHD activity, where 2-OG is used as a cofactor 
[19]; which we observed (Figure 2A)). Furthermore, the 
pro-inflammatory responses of THP-1 cells induced by 
PGN (release of TNF-α and IL-6) were attenuated by 
caffeine (Figure 2E).
The situation with endosomal TLRs 7 and 8 was 
slightly different, where THP-1 cells were exposed to 
0.1 μg/ml R848 with or without 1 h pre-treatment with 
1 mM caffeine. We found that, unlike with PGN, R848-
induced HIF-1α accumulation was significantly reduced 
by caffeine. HIF-1α PHD activity was significantly 
decreased by R848 (as we have reported before [20]), 
but in the presence of caffeine, PHD activity did not 
reduce further and was even slightly elevated compared 
to exposure to R848 alone (Figure 3A). ATP, AMP and 
cAMP levels in the cells were not affected by caffeine 
as in the experiments with PGN (Figure 3B). Caffeine 
inhibited R848-induced XOD activity but also (unlike 
following the exposure of THP-1 cells to PGN) it reduced 
intracellular ROS levels upregulated by R848. In the case 
of endosomal TLRs, XOD contributes to the intracellular 
ROS pool [17] together with NADPH oxidase (Figure 3C). 
This result explains the caffeine-dependent decrease in 
HIF-1α accumulation in THP-1 cells induced by R848, 
since ROS may play a primary role in the process. 
Glycolysis was also significantly upregulated in the 
presence of R848 and this effect was slightly reduced by 
caffeine. 2-OG levels were significantly reduced (by ca. 
50%) by caffeine (Figure 3D). R848-induced production 
of IL-6 and TNF-α were significantly lower in the presence 
of caffeine (Figure 3E).
SCF-induced biological responses of THP-1 cells 
were also affected in a way similar to that observed 
for PGN (see above). THP-1 cells were exposed for 4 
h to 0.1 μg/ml SCF with or without 1 h pre-treatment 
with 1 mM caffeine. We found that SCF-induced HIF-
1α accumulation was not decreased in the presence of 
caffeine which corresponded to a striking decrease in 
HIF-1α PHD activity in the cells (Figure 4A). ATP, cAMP 
and AMP levels were not affected at all (Figure 4B). As 
with TLRs, the Kit receptor, which recognises SCF as a 
ligand, is not a G-protein coupled receptor (it is a typical 
receptor tyrosine kinase), and therefore no changes in 
cAMP levels were observed. SCF-induced XOD activity 
was reduced by caffeine, however intracellular ROS 
levels were slightly upregulated by SCF and remained 
unchanged in the presence of caffeine (Figure 4C). SCF 
also upregulated glycolysis and caffeine attenuated this 
process as well as significantly reduced intracellular 
2-OG levels (Figure 4D). Finally, SCF-induced vascular 
endothelial growth factor (VEGF) production was 
significantly increased upon exposure of the cells to SCF, 
but this process was attenuated by caffeine (Figure 4D).
In order to confirm that caffeine is able to directly 
inhibit XOD and, if so, to characterise this process, 
we studied the kinetics of caffeine effects on purified 
bovine liver XOD activity using the Lineweaver-Burk 
approach [21]. We found that caffeine isosterically (in a 
competitive manner) inhibited XOD (Figure 5). However, 
the Ki was only 4.022 mM suggesting that caffeine is 
a weak inhibitor compared to classic XOD inhibitors 
(for example, allopurinol and sodium tungstate). This 
confirmed our previous studies showing the ability of 
caffeine to inhibit XOD in vitro but not in vivo due to 
demethylation of the drug.
Caffeine affects SCF-induced responses of 
primary human AML cells in an mTOR-
dependent manner
We sought confirmation of our results using primary 
human leukocytes. For this purpose we used primary acute 
myeloid leukaemia cells AML-PB001F purchased from 
AllCells (Alameda, CA, USA). Cells were exposed to 
0.1 μg/ml SCF (these cells express high levels of the Kit 
receptor) for 4 h with or without 1 h pre-treatment with 
1 mM caffeine. We found that SCF induced a significant 
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Figure 2: Effects of caffeine on TLR2-mediated biological responses of THP-1 cells. Cells were exposed for 4 h to PGN with 
or without 1 h pre-treatment with 1 mM caffeine before assessing the indicated biological responses: A. HIF-1α accumulation, B. ATP/
cAMP/AMP levels, C. XOD activity and intracellular ROS pool, D. glycolysis and 2-OG level as well as E. TNF-α/IL-6 release. Western 
blot data show one representative experiment of three that gave similar results. Quantitative data are shown as means ± S.D; * – p < 0.01 
vs. control (n = 3), a – p < 0.01 vs. PGN alone.
Figure 3: Effects of caffeine on TLR7/8-mediated biological responses of THP-1 cells. Cells were exposed for 4 h to R848 with 
or without 1 h pre-treatment with 1 mM caffeine before analysing A. HIF-1α accumulation, B. ATP/cAMP/AMP levels, C. XOD activity 
and intracellular ROS pool, D. glycolysis and 2-OG level as well as E. TNF-α/IL-6 release. Western blot data show one representative 
experiment of three that gave similar results. Quantitative data are shown as means ± S.D; * – p < 0.01 vs. control (n = 3), b – p < 0.01 vs. 
R848 alone.
Figure 4: Effects of caffeine on SCF-induced Kit receptor activation in- THP-1 cells. Cells were exposed for 4 h to SCF with 
or without 1 h pre-treatment with 1 mM caffeine before analysing A. HIF-1α accumulation, B. ATP/cAMP/AMP levels, C. XOD activity 
and intracellular ROS pool, D. glycolysis and 2-OG level as well as VEGF release. Western blot data show one representative experiment 
of three that gave similar results. Quantitative data are shown as means ± S.D; * – p < 0.01 vs. control (n = 3), c – p < 0.01 vs. SCF alone.
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increase in mTOR phosphorylation at position S2448 and 
respectively phosphorylation of its substrates – p70 S6K1 
and eIF4E-BP1 (Figure 6A). These levels were compared 
with those in resting primary human leukocytes (PL) 
obtained from healthy donors (Figure 6A). As in THP-1 
cells, SCF induced significant upregulation of HIF-1α 
accumulation, glycolysis, VEGF release and XOD activity. 
All these effects were attenuated by caffeine (in the case of 
HIF-1α – downregulated; the level was still significantly 
higher than the control) (Figure 6B). Interestingly, 
background levels of HIF-1α, pS2448 mTOR and XOD 
activity were significantly higher in primary AML 
cells compared to primary “healthy” leukocytes (PL) 
suggesting that these factors/pathways are crucial for 
AML cell function. Importantly, resting primary human 
leukocytes obtained from the blood of healthy donors did 
not accumulate detectable amounts of HIF-1α protein.
Given the effects of caffeine on AML cell 
function, we next determined the concentration-
dependent actions of caffeine on these cells following 
exposure to 0.1 μg/ml SCF for 4 h with or without 1 h 
pre-treatment with 0.01, 0.1 and 1 mM caffeine. Levels 
of pS2448 mTOR were monitored as a biochemical 
response. We found that SCF-dependent mTOR 
phosphorylation was significantly affected by 1 and 0.1 
but not 0.01 mM caffeine (Figure 7).
Caffeine downregulates anti-IgE-induced 
activation of human basophils by affecting 
mTOR signalling
We were next interested in investigating the effects 
of caffeine on primary human basophils. These terminally 
differentiated granulocytes display biochemically similar 
but pathophysiologically different responses compared to 
THP-1 and primary AML cells. Furthermore, basophils 
play a crucial role in human allergic reactions since they 
readily respond to IgE-dependent triggering, although 
compared to leukaemic myeloid cells they are relatively 
unresponsive to SCF [22] and TLR2/4 ligands [23]. 
Stimulation of primary human basophils with 1 μg/ml 
anti-IgE led to the activation of mTOR phosphorylation 
at S2448, which was attenuated by caffeine (Figure 8). 
Similar effects were observed regarding the phos-
phorylation of mTOR substrates (Figure 8).
As shown previously [24], HIF-1α accumulation 
was upregulated by anti-IgE. This process was completely 
blocked by caffeine and the process appeared to be 
independent of PHD activity, since no significant 
changes were observed in enzyme activity (Figure 9A). 
Importantly, we could not detect any XOD activity 
in basophils, which is supported by our previous 
observations [21]. Western blot analysis (Figure 9A) 
demonstrated the absence of XOD protein in basophils. 
ATP and AMP levels were not affected by any of the 
treatments; however, cAMP levels were significantly 
upregulated by anti-IgE and were further increased in the 
presence of 1 mM caffeine (Figure 9B). This suggests that 
IgE-induced responses in basophils are indirectly linked 
to G-protein-coupled receptor signalling, possibly due 
to the actions of histamine acting through H2 receptors, 
which may serve as a negative feedback loop limiting 
further basophil degranulation and histamine release. 
Intracellular ROS levels were not affected which confirms 
our previous findings suggesting that IgE-induced 
basophil responses are orchestrated in a redox-independent 
manner (Figure 9C). IgE-dependent histamine release 
was significantly affected by caffeine which is in line 
with the observed caffeine-dependent downregulation 
of IgE-induced glycolysis and 2-OG levels (Figure 9D). 
However, the effect associated with 2-OG levels did not 
impact HIF-1α accumulation or PHD activity, further 
confirming our hypothesis that this process is most likely 
to be PHD-independent in basophils.
Figure 5: Caffeine is a weak competitive inhibitor of XOD. Kinetics of the effects of caffeine on the activity of purified bovine 
liver XOD were analysed as described in the Materials and methods. Each point was analysed in quadruplicate.
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Figure 6: Effects of caffeine on SCF-induced Kit receptor activation in primary human AML cells. AML-PB001F cells 
were exposed for 4 h to SCF with or without 1 h pre-treatment with 1 mM caffeine before analysis of A. mTOR phosphorylation and its 
biological activity and B. HIF-1α accumulation, glycolysis, VEGF release and XOD activity. Western blot data (50,000 cells per well were 
loaded in each case for AML cells and 90,000 for healthy primary leucocytes) show one representative experiment of three-four (using cells 
derived from different donors) that gave similar results. In both panels A and B we also show the results obtained from non-treated healthy 
primary human leukocytes (PL) handled as described in Materials and Methods. Quantitative data are shown as means ± S.D; * – p < 0.01 
vs. control (n = 4 for panel A and n = 3 for panel B), d – p < 0.01 vs. SCF alone.
Figure 7: Dose-dependent effects of caffeine on SCF-induced Kit receptor-mediated intracellular pS2448 mTOR 
levels. AML-PB001F cells were exposed for 4 h to 0.1 μg/ml of SCF with or without 1 h pre-treatment with 0.01, 0.1 or 1 mM caffeine. 
pS2448 mTOR levels were analysed. Quantitative data are shown as means ± S.D of three individual experiments; * – p < 0.01 vs. control.
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Figure 8: Caffeine inhibits ligand-induced mTOR signalling pathway in primary human basophils. Cells were exposed for 2 h to 
0.1 μg/ml anti-IgE with or without 30 min pre-treatment with 1 mM caffeine. pS2448 and pT2446 phospho-mTOR levels as well as phosphorylation 
of its downstream enzymes were analysed as described in Materials and Methods. Western blot data show one representative experiment of four 
that gave similar results. Quantitative data are shown as means ± S.D; * – p < 0.01 vs. control (n = 4), e – p < 0.01 vs. anti-IgE alone.
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We next further verified the differential involvement 
of XOD in the biological responses of myeloid cells 
by assessing whether basophil function could be 
affected by XOD inhibitors/substrate. We studied the 
effects of the XOD inhibitor allopurinol, the XOD sub-
strate hypoxanthine (hypoxanthine – chemically is an 
allopurinol isomer) and the highly specific XOD inhibitor 
sodium tungstate. Neither of these compounds, however, 
was able to significantly affect anti-IgE-stimulated 
basophil histamine release and HIF-1α accumulation 
(Supplementary Figure S1). We also noticed that, while 
0.01 mM caffeine did not significantly inhibit IgE-
induced histamine release, HIF-1α accumulation was 
still markedly reduced at this low caffeine concentra-
tion (Supplementary Figure S1). This provides further 
confirmation of our previous observations [24] suggesting 
that histamine release and HIF-1 activation are controlled 
by biochemically independent pathways.
Caffeine is taken up but not metabolised by 
human myeloid cells
In order to ascertain whether the observed effects 
described above were due to caffeine or a metabolite 
we investigated whether the different myeloid cell 
types employed in the study could metabolised caffeine 
following cellular uptake. We found that neither 
THP-1 cells nor primary human leukocytes nor basophils 
contained the cytochrome P450 1A2 isoform which is 
primarily responsible for caffeine demethylation (data 
not shown since they are at zero levels). We then assessed 
whether caffeine (a) enters the studied cells and (b) is 
metabolised through other pathways. For this purpose we 
used high-performance liquid chromatography (HPLC) in 
order to detect caffeine and its metabolites. As a positive 
control we used urine of healthy volunteers following 
consumption of caffeine by them. In the urine we detected 
six caffeine metabolites as well as unmodified caffeine, 
suggesting that all the metabolites are detectable by our 
method and that caffeine is mostly metabolised in vivo 
in humans (Figure 10). In both THP-1 cells and primary 
human basophils we detected caffeine but none of its 
metabolites, suggesting that caffeine is endocytosed into 
these myeloid cells but is not further metabolised. This 
finding was confirmed by the fact that none of the caffeine 
metabolites was detected in the culture medium; only 
unmodified caffeine was detected (Figure 10). These data 
suggest that the effects of caffeine observed in the study 
were solely caused by unmodified caffeine.
Taken together, our results demonstrate for the first 
time that caffeine affects the biological responses of human 
myeloid cells, including leukaemia cell lines, primary AML 
cells and primary human basophils by downregulating the 
mTOR pathway and differentially inhibiting XOD.
DISCUSSION
Caffeine, a plant-derived purine alkaloid, was 
chemically identified over 100 years ago and its effects 
were observed even before Biochemistry developed 
into an independent field of science [1]. However, due 
to its metabolism and labile properties, the effects of 
caffeine in human hematopoietic cells (where it remains 
unmetabolised) were completely overlooked. Given the fact 
that some purine compounds were found to directly inhibit 
mTOR, we were interested to see whether caffeine displays 
such an activity too. Alternatively, unmodified caffeine was 
found to inhibit XOD, which we recently showed to play 
a major role in myeloid cell responses. We were therefore 
interested in discovering whether caffeine plays a major role 
Figure 9: Effects of caffeine on the anti-IgE-induced biological responses of primary human basophils. Cells were 
exposed for 2 h to 0.1 μg/ml anti-IgE with or without 30 min pre-treatment with 1 mM caffeine before analysis of A. HIF-1α accumulation 
and XOD protein levels, B. ATP/cAMP/AMP levels, C. intracellular ROS pool and histamine release, D. glycolysis and 2-OG level. 
Western blot data show one representative experiment of three that gave similar results. Quantitative data are shown as means ± S.D ; * – p 
< 0.01 vs. control (n = 3), e – p < 0.01 vs. anti-IgE alone.
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in the biological responses of human hematopoietic cells of 
myeloid lineage based on its potential actions on XOD and 
mTOR. These leukocytes determine human innate immune 
responses and are affected during severe human disorders 
such as AML and allergy. Thus, elucidating a potentially 
overlooked mechanism of caffeine may result in additional 
therapeutic uses for this methylxanthine which was rapidly 
taken up by these myeloid cells but not metabolised.
We analysed the effects of caffeine on the pro-
inflammatory and pro-leukaemic responses of human 
AML cells using THP-1 cell line and primary AML cells 
as well as on the pro-allergic reactions of primary human 
basophils. Caffeine was found to downregulate activating 
phosphorylation (S2448 position) of the mTOR protein thus 
affecting its kinase activity. This occurred in both THP-1 
cells (upon exposure to PGN, R848 and SCF) as well as in 
primary AML cells stimulated with SCF (TLR expression 
levels are quite low in these cells). Importantly, caffeine did 
not increase phosphorylation of the T2446 residue of mTOR. 
This shows that caffeine does not activate specific mTOR 
downregulatory cascades, for example the AMPK pathway 
[10]. Intracellular AMP (specific AMP kinase activator) 
levels were also not affected by caffeine. However, caffeine 
inhibited XOD activity in both THP-1 and primary AML 
cells. Our previous studies showed that inhibition of XOD by 
allopurinol or sodium tungstate led to a significant increase 
in intracellular AMP levels and therefore induced AMPK-
dependent downregulatory phosphorylation of mTOR 
at position T2446 [21]. Here, we also observed inhibition 
of XOD but without increases in intracellular AMP 
levels. Recently, it was reported that caffeine is capable 
of inhibiting Akt phosphorylation thus preventing mTOR 
activation (presumably through phosphorylation of its 
S2448 residue). However, other studies demonstrated that, 
in tissues expressing high levels of XOD (for example 
skeletal muscles), high concentrations of caffeine (10 mM) 
activate AMPK [7]. These tissues, however, can metabolise 
caffeine. XOD expression in leukocytes (even in AML cells) 
Figure 10: Determination of caffeine and its metabolites in human urine and myeloid cells. Caffeine and its metabolites 
in human urine (coffee drinkers) and medium/lysates of THP-1 cells (exposed for 4 h to 1 mM caffeine) and human basophils (exposed 
for 2 h to 1 mM caffeine) were detected by HPLC. The caffeine metabolic pathway in humans is also presented indicating how each 
metabolite is obtained biochemically. CYP4501A – cytochrome P450 A2; XOD – xanthine oxidase; NAT2 – N-acetyltransferase 2; 
AAMU – 5 Acetylamino-6-amino-3-methyluracil; AFMU – 5 Acetylamino-6-formylamino-3-methyluracil.
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is relatively low compared to other tissues and in basophils 
where the presence of XOD was even undetectable [21].
Although caffeine is a weak inhibitor of XOD 
compared to allopurinol and especially sodium tungstate, it 
might affect the re-use of purines in myeloid cells (this system 
is quite robust in leukocytes and is not affected by allopurinol 
or tungastates, which are specific XOD inhibitors only – 
especially tungstates, where tungsten replaces molybdenum 
in the catalytic site of the enzyme causing its irreversible 
inhibition). Caffeine is known to inhibit HGPRT, however, in 
myeloid cells its inhibitory effects are more striking since it 
is not metabolised in these cells [25]. This means that, upon 
inhibition of XOD by caffeine, levels of hypoxanthine are 
increased. However, hypoxanthine can’t be converted into 
IMP and further down to AMP [21] (for more details, see 
Supplementary Figure S2). This lack of increase in AMP 
levels prevents the activation of AMP kinase and subsequent 
phosphorylation of mTOR at T2446.
Inhibition of mTOR and XOD by caffeine did 
not lead to the attenuation of HIF-1α accumulation in 
THP-1 and primary AML cells. This was due to a significant 
decrease in HIF-1α PHD activity (resulting from the 
decrease in intracellular 2-OG levels required for this 
reaction in form of a co-factor). Caffeine activates lipolysis 
by upregulating the activity of hormone-sensitive lipase 
(HSL), which is well expressed in myeloid cells [4, 25]. 
This leads to a decrease in glycolysis, which is further 
supported by a decrease in mTOR kinase activity which 
is required for translation of glycolytic enzymes [18, 26]. 
Such an effect results in the upregulation of the Krebs’ 
cycle and thus in a decrease in intracellular 2-OG levels that 
affect HIF-1α PHD activity, thus preventing physiological 
degradation of HIF-1α protein. The effects described above 
are summarised in the scheme presented in the Figure 11.
Caffeine was revealed to inhibit mTOR, thus 
downregulating glycolysis. Previous reports suggested 
a possible influence of caffeine on NF-kB activity and 
calcium-dependent signalling [7, 27]. All these effects 
are likely to be responsible for the decreases in cytokine 
production observed in the present study (e.g. TNF-α and 
IL-6 in the case of TLR ligand stimulation and VEGF 
when the cells were exposed to SCF). These effects took 
place in both THP-1 and primary AML cells.
Despite the well-known fact that caffeine is an 
effective inhibitor of cAMP-PDE [2], no significant changes 
in intracellular cAMP levels were observed in THP-1 or 
AML cells. This could be explained by the fact that neither 
TLRs nor the SCF receptor (Kit) are G-protein coupled 
receptors. Therefore, they do not activate adenylate cyclase, 
the enzyme, which converts ATP into cAMP.
A different picture was observed in primary human 
basophils which did not express detectable amounts of 
XOD. Here, we also observed inhibition of IgE-induced 
mTOR kinase activity and abrogation of the mediator 
(histamine) release. However, HIF-1α accumulation 
did not seem to be PHD dependent in these cells and 
therefore, upon inhibition of mTOR kinase activity, 
IgE-induced HIF-1α accumulation was attenuated by 
caffeine. However, in contrast to AML and THP-1 cells, 
we observed a significant increase in intracellular cAMP 
levels in basophils which were further upregulated by 
caffeine. Basophils release histamine and also express 
H2-type histamine receptors which are G-protein-coupled 
and thus activate adenylate cyclase [15]. The cAMP levels 
induced by the autocrine actions of histamine are therefore 
preserved by caffeine as an inhibitor of cAMP-PDE. In 
this case, it is likely that we observed additional inhibition 
of mTOR activation due to the indirect actions of caffeine 
by increasing cAMP. All the effects reported were studied 
at 1 mM caffeine. However, dose-response investigations 
demonstrated that it displays its activities in primary AML 
cells and basophils at 0.1 mM though not at 0.01 mM.
Taken together, our results demonstrate, for the first 
time, that unmodified caffeine inhibits mTOR function by 
targeting its kinase activity during the biological responses 
of various human myeloid cells. These findings support 
observations made by other groups regarding caffeine effects 
on the mTOR pathway in non-blood cells [7, 8]. Furthermore, 
caffeine inhibits XOD activity but, unlike XOD-specific 
inhibitors, it does not upregulate the re-use of purines in 
AML cells. In contrast, basophils do not express detectable 
amounts of XOD. Since caffeine is a non-toxic drug with 
relatively few side effects at therapeutic concentrations, and 
easily metabolised in non-blood cells, our findings may lead 
to new avenues for therapy of human disorders affecting 
myeloid hematopoietic cells. However, it is obvious that 
high concentrations of caffeine would need to be maintained 
in order to achieve either its anti-inflammatory/anti-allergic 
effects or to affect SCF-induced biological responses. 
Because of this, the therapeutic actions of caffeine would 
more likely be achieved following external applications of 
this drug. For example, caffeine could be applied as a cream 
supplement or through other forms of direct application 
of unmodified caffeine on target myeloid cells with the 
purpose of their inactivation or elimination (previous studies 
have shown the ability of caffeine to induce programmed 
cell death [7, 8]). Alternatively, for internal applications, 
one might consider the recently discovered advantages of 
Nanobiotechnology or other highly specific forms of drug 
delivery in order to supply caffeine directly to myeloid cells.
MATERIALS AND METHODS
Materials
RPMI-1640 medium, foetal calf serum and 
supplements, caffeine, bovine liver XOD, PGN, goat anti-
human-IgE, caffeine metabolites and an ATP luminometric 
detection kit were purchased from Sigma (Suffolk, UK). 
AMP/cAMP detection kits were purchased from Promega 
(Southampton, UK). Maxisorp™ microtitre plates were 
obtained from Nunc (Roskilde, Denmark) as well as from 
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Oxley Hughes Ltd (London, UK). Mouse monoclonal 
antibodies to HIF-1α, mTOR and β-actin as well as rabbit 
polyclonal antibodies against phospho-S2448 mTOR and 
phospho-T2446 mTOR were from Abcam (Cambridge, 
UK). Antibodies against phospho-T389 p70 S6 kinase 1 
(p70 S6K1), total and phospho-S65 eukaryotic initiation 
factor 4E binding protein 1 (eIF4E-BP1) antibodies were 
obtained from Cell Signalling Technology (Danvers, MA 
USA). Goat anti-mouse and goat anti-rabbit fluorescence 
dye-labelled antibodies were obtained from Li-Cor 
(Lincoln, Nebraska USA). ELISA-based assay kits for 
the detection of IL-6, TNF-α and VEGF were purchased 
from R&D Systems (Abingdon, UK). All other chemicals 
were of the highest grade of purity that were commercially 
available (from either Sigma or Fisher Scientific).
THP-1 human myeloid cells
THP-1 human leukaemia monocytic macrophages 
were obtained from the European collection of Cell Cultures 
(Salisbury, UK). Cells were cultured in RPMI 1640 media 
supplemented with 10% foetal calf serum, penicillin (50 IU/
ml) and streptomycin sulfate (50 μg/ml). Cells used in the 
experiments were from the 5–35th passage.
Primary human AML cells
Primary human AML mononuclear cells (AML-
PB001F, newly diagnosed/untreated) were purchased from 
AllCells (Alameda, CA, USA) and handled in accordance 
with manufacturer’s instructions. Cells derived from two 
different patients were used in the experiments.
Primary human leukocytes obtained from 
healthy donors
Primary human leukocytes were obtained from buffy 
coat blood (prepared from healthy donors) purchased from 
the National Health Blood and Transfusion Service (NHSBT, 
UK) following ethical approval (REC reference: 12/
WM/0319). Mononuclear-rich leukocytes were obtained by 
Ficoll-density centrifugation according to the manufacturer’s 
Figure 11: Possible biochemical mechanisms of the effects of caffeine on the mTOR pathway, HIF-1 activity and 
energy metabolism in human myeloid cells (SCF-induced responses are used as the example). Additional abbreviations 
used: HK – hexokinase, PGI – phosphoglucose isomerase, PFK – phosphofructokinase, AL – Aldolase, TPI – Triose-phosphate isomerase, 
GPDH – glyceraldehyde-3-phosphate dehydrogenase, PGK – phosphoglycerate kinase, PGM – phosphoglycerate mutase, EL – enolase, 
PK – pyruvate kinase, LDH – lactate dehydrogenase, DHAP – dihydroxyacetone phosphate, GA3-P – glyceraldehyde-3-phosphate, 3-PG – 
3-phosphoglycerate, 2-PG – 2-phosphoglycerate, PEP – phosphoenolpyruvate, GLT1/3 – glucose transporters 1/3, TSC1/TSC2 – Tuberous 
sclerosis proteins 1 and 2, PDK – P-3-PI-dependent kinase, ADK – adenylate kinase, TK – tyrosine kinase.
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protocol. Cell numbers were determined using a haemocy-
tometer and diluted accordingly with HEPES-buffered 
Tyrode’s solution before treatment as indicated.
Primary human basophils
Primary human basophils were obtained from buffy 
coats and isolated from the leukocyte-rich fraction obtained 
by Ficoll density centrifugation as described above. Basophils 
were then purified by a negative selection procedure to 
90–100% purity (as judged by alcian blue staining) using 
a commercially available kit, as previously described [28]. 
Basophils were pre-incubated for 15 min at 37°C in HEPES-
buffered Tyrode’s solution and then treated as indicated.
Stem cell factor
Human SCF protein was produced in E.Coli and 
purified in accordance with published protocols [29].
Western blot analysis
Expressions of HIF-1α, total and phospho-T389 
p70 S6K1, total and phospho-S65 eIF4E-BP1 as well as 
XOD protein levels were determined by Western blot 
analysis and compared to β-actin in order to determine 
equal protein loading, as previously described [10]. Li-Cor 
goat secondary antibodies, conjugated with fluorescent 
dyes, were used according to the manufacturer’s protocol 
in order to visualise the proteins of interest using a Li-Cor 
Odyssey imaging system. Western blot data were subjected 
to quantitative analysis using Odyssey software and values 
were normalised against respective β-actin bands.
Detection of phospho-S2448 and phospho-T2446 
mTOR in cell lysates by ELISA
Phosphorylation of mTOR was monitored using 
ELISA assays as recently described [10, 21, 30]. Briefly, 
the ELISA plates were coated with mouse anti-mTOR 
antibodies and blocked with 2% BSA. Cell lysates were 
then added to the wells and kept at room temperature for 
at least 2 h (under constant agitation). After extensive 
washing with TBST buffer, anti-phospho-S2448 (or anti-
phospho-T2446) mTOR antibody was added and plates 
were incubated for at least 2 h at room temperature with 
constant agitation. Plates were then washed with TBST 
buffer and incubated with 1:1000 HRP-labelled goat anti-
rabbit IgG in TBST buffer. After extensive washing with 
TBST, bound secondary antibodies were then detected by 
the peroxidase reaction (ortho-phenylenediamine/H2O2).
HIF-1α PHD assay
To detect HIF-1α PHD activity we employed 
a peptide-based assay [31]. HIF-1α-free cell lysates 
were used to avoid the impact of intracellular HIF-1α 
hydroxylation. Lysates of non-treated and treated THP-
1 cells were incubated for one hour in 96-well ELISA 
plates which were coated with HIF-1α capture antibodies 
and blocked with BSA as described previously. Lysates 
were then subjected PHD assay following this incubation 
period.
Detection of intracellular ATP, cAMP, AMP, 
ROS and 2-OG levels, xanthine oxidase activity 
as well as glycolysis intensity
ATP was detected using a commercial luminometric 
kit (Sigma) according to the manufacturer’s protocol. 
AMP and cAMP levels were detected using luminometric 
assay kits in accordance with manufacturer’s protocols. 
Intracellular ROS levels were also monitored by 
luminometric assay as previously described [32]. 2-OG 
levels were analysed using a glutamate dehydrogenase 
spectrophotometric assay [33]. Xanthine oxidase activity 
was measured as described before [21]. The intensity of 
glycolysis was determined based on the ability cell lysate 
enzymes, used as a multienzyme preparation, to convert 
glucose into lactate under anaerobic conditions, which was 
achieved by employing an anaerobic chamber [10].
Detection of IL-6, TNF-α and VEGF release
Concentrations of these cytokines released into the 
cell culture media were analysed by ELISA (R&D Systems 
assay kit) according to the manufacturer’s protocol.
Measurement of histamine release
Histamine releases were assessed using spectro-
fluorometic autoanalysis as previously described [34]. 
Histamine releases were calculated from the histamine 
contents released into the supernatants as a percentage of 
total histamine content present in lysed cell pellets.
High performance liquid chromatography
Caffeine and its metabolites were analysed in urine 
according to a previously described protocol [35, 36] 
with minor modifications. Healthy subjects were asked 
to refrain from all caffeine containing beverages and 
chocolate for 1 day. At 8 a.m. on the test day subjects 
were asked to consume 2 cups of very strong espresso 
(approximately 200 mg of caffeine) and 6 hours later urine 
was collected for analysis.
10 ml of urine were mixed with 200 mg of ascorbic 
acid. The pH was adjusted to 3.5 with 30% acetic acid. 
200 μl of urine were mixed with 140 mg of ammonium 
sulfate, 25 μl of internal standard (137 MU) and vortexed 
at full speed for 1 min. The metabolites were extracted 
with chloroform:isopropanol (95:5) and centrifuged. The 
organic phase was evaporated to dryness using nitrogen or 
Speedvac and the pellet was dissolved in 750 μl of diluent 
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containing MeOH : acetic acid : water (20:0.5:979.5 
vol:vol:vol) and 5 μl of the sample was analysed by 
Agilent HPLC system (the flow rate was 0.5 ml/min) 
with a UV detector using a gradient elution profile. 
Caffeine, caffeine metabolites and the internal standard 
were separated on an Agilent XBD C18 reverse phase 
column (1.8 μm, 4.6 × 50 mm). The solvents used for the 
elution were mobile phase A containing MeOH : acetic 
acid : water (20:0.5:979.5 vol:vol:vol) and mobile phase 
B (MeOH : acetic acid : water 700:0.5:229.5 vol:vol:vol). 
The gradient program was 0% B (0 min), 100% (0.1 to 15 
min) and 0% (15.1 to 18 min). The analytes were detected 
by UV absorbance at 280 nm. Calibration curves were 
developed using known amounts of metabolites.
Analysis of total cytochrome P450 and activity of 
CYP450 1A2
Total CYP450 was analysed by a classic 
spectrophotometric method initially proposed by Omura 
and Sato [37]. CYP450 1A2 activity was analysed based 
on its ability to oxidise caffeine using NADPH as a donor. 
Mouse liver homogenates obtained from commercial 
sources were used as positive control.
Statistical analysis
Each experiment was performed at least three times 
and statistical analysis was conducted using a two-tailed 
Student’s t test. Statistical probabilities (p) were expressed 
as *, where p < 0.01.
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